BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33241676)

  • 1. The epigenetic regulator RINF (CXXC5) maintains
    Astori A; Matherat G; Munoz I; Gautier EF; Surdez D; Zermati Y; Verdier F; Zaidi S; Feuillet V; Kadi A; Lauret E; Delattre O; Lefèvre C; Fontenay M; Ségal-Bendirdjian E; Dusanter-Fourt I; Bouscary D; Hermine O; Mayeux P; Pendino F
    Haematologica; 2022 Jan; 107(1):268-283. PubMed ID: 33241676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXXC5 (retinoid-inducible nuclear factor, RINF) is a potential therapeutic target in high-risk human acute myeloid leukemia.
    Astori A; Fredly H; Aloysius TA; Bullinger L; Mansat-De Mas V; de la Grange P; Delhommeau F; Hagen KM; Récher C; Dusanter-Fourt I; Knappskog S; Lillehaug JR; Pendino F; Bruserud Ø
    Oncotarget; 2013 Sep; 4(9):1438-48. PubMed ID: 23988457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional involvement of RINF, retinoid-inducible nuclear factor (CXXC5), in normal and tumoral human myelopoiesis.
    Pendino F; Nguyen E; Jonassen I; Dysvik B; Azouz A; Lanotte M; Ségal-Bendirdjian E; Lillehaug JR
    Blood; 2009 Apr; 113(14):3172-81. PubMed ID: 19182210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rinf Regulates Pluripotency Network Genes and Tet Enzymes in Embryonic Stem Cells.
    Ravichandran M; Lei R; Tang Q; Zhao Y; Lee J; Ma L; Chrysanthou S; Lorton BM; Cvekl A; Shechter D; Zheng D; Dawlaty MM
    Cell Rep; 2019 Aug; 28(8):1993-2003.e5. PubMed ID: 31433977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.
    Zhou L; McMahon C; Bhagat T; Alencar C; Yu Y; Fazzari M; Sohal D; Heuck C; Gundabolu K; Ng C; Mo Y; Shen W; Wickrema A; Kong G; Friedman E; Sokol L; Mantzaris I; Pellagatti A; Boultwood J; Platanias LC; Steidl U; Yan L; Yingling JM; Lahn MM; List A; Bitzer M; Verma A
    Cancer Res; 2011 Feb; 71(3):955-63. PubMed ID: 21189329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling.
    Bhagat TD; Zhou L; Sokol L; Kessel R; Caceres G; Gundabolu K; Tamari R; Gordon S; Mantzaris I; Jodlowski T; Yu Y; Jing X; Polineni R; Bhatia K; Pellagatti A; Boultwood J; Kambhampati S; Steidl U; Stein C; Ju W; Liu G; Kenny P; List A; Bitzer M; Verma A
    Blood; 2013 Apr; 121(15):2875-81. PubMed ID: 23390194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer.
    Knappskog S; Myklebust LM; Busch C; Aloysius T; Varhaug JE; Lønning PE; Lillehaug JR; Pendino F
    Ann Oncol; 2011 Oct; 22(10):2208-15. PubMed ID: 21325450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
    Pellagatti A; Jädersten M; Forsblom AM; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Hellström-Lindberg E
    Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11406-11. PubMed ID: 17576924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.
    Chesnais V; Arcangeli ML; Delette C; Rousseau A; Guermouche H; Lefevre C; Bondu S; Diop M; Cheok M; Chapuis N; Legros L; Raynaud S; Willems L; Bouscary D; Lauret E; Bernard OA; Kosmider O; Pflumio F; Fontenay M
    Blood; 2017 Jan; 129(4):484-496. PubMed ID: 27856460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia.
    Man N; Mas G; Karl DL; Sun J; Liu F; Yang Q; Torres-Martin M; Itonaga H; Martinez C; Chen S; Xu Y; Duffort S; Hamard PJ; Chen C; Zucconi BE; Cimmino L; Yang FC; Xu M; Cole PA; Figueroa ME; Nimer SD
    JCI Insight; 2021 Oct; 6(19):. PubMed ID: 34622806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia.
    Wong JJ; Lau KA; Pinello N; Rasko JE
    Cancer Sci; 2014 Nov; 105(11):1457-63. PubMed ID: 25220401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes.
    Tehranchi R; Invernizzi R; Grandien A; Zhivotovsky B; Fadeel B; Forsblom AM; Travaglino E; Samuelsson J; Hast R; Nilsson L; Cazzola M; Wibom R; Hellström-Lindberg E
    Blood; 2005 Jul; 106(1):247-53. PubMed ID: 15755901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic dysregulation of GATA1 is involved in myelodysplastic syndromes dyserythropoiesis.
    Hopfer O; Nolte F; Mossner M; Komor M; Kmetsch A; Benslasfer O; Reissmann M; Nowak D; Hoelzer D; Thiel E; Hofmann WK
    Eur J Haematol; 2012 Feb; 88(2):144-53. PubMed ID: 21967505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulation of TET2 in CD3⁺ and CD34⁺ cells of myelodysplastic syndromes and enhances CD34⁺ cells proliferation.
    Zhang W; Shao Z; Fu R; Wang H; Li L; Liu H
    Int J Clin Exp Pathol; 2015; 8(9):10840-6. PubMed ID: 26617797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.
    Eisenmann KM; Dykema KJ; Matheson SF; Kent NF; DeWard AD; West RA; Tibes R; Furge KA; Alberts AS
    Oncogene; 2009 Oct; 28(39):3429-41. PubMed ID: 19597464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS.
    Follo MY; Marmiroli S; Faenza I; Fiume R; Ramazzotti G; Martelli AM; Gobbi P; McCubrey JA; Finelli C; Manzoli FA; Cocco L
    Adv Biol Regul; 2013 Jan; 53(1):2-7. PubMed ID: 23058275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [EVI1 and its role in myelodysplastic syndrome, myeloid leukemia and other malignant diseases].
    Fuchs O
    Cas Lek Cesk; 2006; 145(8):619-24. PubMed ID: 16995417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct expression profiles of MSI2 and NUMB genes in myelodysplastic syndromes and acute myeloid leukemia patients.
    Pereira JK; Traina F; Machado-Neto JA; Duarte Ada S; Lopes MR; Saad ST; Favaro P
    Leuk Res; 2012 Oct; 36(10):1300-3. PubMed ID: 22784712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice.
    Chen TH; Kambal A; Krysiak K; Walshauser MA; Raju G; Tibbitts JF; Walter MJ
    Blood; 2011 Feb; 117(5):1530-9. PubMed ID: 21123823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
    Blatt K; Herrmann H; Hoermann G; Willmann M; Cerny-Reiterer S; Sadovnik I; Herndlhofer S; Streubel B; Rabitsch W; Sperr WR; Mayerhofer M; Rülicke T; Valent P
    Clin Cancer Res; 2014 Jul; 20(13):3589-602. PubMed ID: 24799522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.